Abstract
It is believed, but not well established, that renal dysfunction increases the risk of adverse bleeding events associated with dual antiplatelet therapy (DAPT), especially in patients with acute coronary syndrome (ACS). The aim of this study is to estimate the impact of renal function on adverse bleeding events associated with DAPT in patients with ACS. A total of 1,264 ACS patients who received DAPT, clopidogrel (n = 530) or prasugrel (n = 734) in addition to aspirin, were assessed in a multicenter observational study. The relationship between renal function and bleeding event, defined as BARC 3 or 5, was determined using a marginal effect from the logit model and Royston-Parmar model. During an average 313.1 days of the observation period, defined as the duration of DAPT after admission until the implementation of a change in the regimen, bleeding events were observed in 7.4% of patients (n = 94). The estimated curves demonstrated that the probability of bleeding was positive correlated with renal dysfunction (6.0 to 8.6), regardless of the DAPT regimen used. This probability was consistently higher in clopidogrel (7.4 to 10.5) than in prasugrel (4.8 to 0.7). This trend was also shown in maintenance hemodialysis patients (6.7 vs. 10.3). Estimated cumulative incidences among individual stages of renal function were drawn. In conclusion, bleeding events increased with worsening renal function, and prasugrel is safer than clopidogrel as a component of DAPT throughout all levels of renal function, including hemodialysis patients after ACS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bonello L, Laine M, Lemesle G, Puymirat E, Dabry T, Thuny F, et al. Meta-analysis of potent P2Y12-ADP receptor antagonist therapy compared to clopidogrel therapy in acute coronary syndrome patients with chronic kidney disease. Thromb Haemost. 2018;118:1839–46.
Mavrakanas TA, Chatzizisis YS, Gariani K, Kereiakes DJ, Gargiulo G, Helft G, et al. Duration of dual antiplatelet therapy in patients with CKD and drug-eluting stents: a meta-analysis. Clin J Am Soc Nephrol. 2019;14:810–22.
Kao CC, Wu MS, Chuang MT, Lin YC, Huang CY, Chang WC, et al. Investigation of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease. PLoS ONE. 2021;16: e0255645.
National KF. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-266.
Kidney Disease: Improving Global Outcomes Blood Pressure Work G. Clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;2021(99):S1–87.
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Circulation. 2018;138:e618–51.
Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation. 2019;140:240–61.
Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736–47.
Lambert PC. Flexible parametric survival analysis using Stata. College Station: STATA press; 2011. p. 1–339.
Lambert PC, Wilkes SR, Crowther MJ. Flexible parametric modelling of the cause-specific cumulative incidence function. Stat Med. 2017;36:1429–46.
Fujii T, Endo S, Tsuchiya R, Nagamatsu H, Kasai S, Kawamura Y, et al. Estimation of adverse events associated with P2Y12 receptor inhibitors stratified by academic research consortium for high bleeding risk criteria in acute coronary syndrome. Int J Cardiol. 2023. https://doi.org/10.1016/j.ijcard.2023.01.020.
Ndrepepa G, Lahu S, Aytekin A, Scalamogna M, Coughlan JJ, Gewalt S, et al. One-year ischemic and bleeding events according to renal function in patients with non-ST-segment elevation acute coronary syndromes treated with percutaneous coronary intervention and third-generation antiplatelet drugs. Am J Cardiol. 2022;176:15–23.
Wohrle J, Seeger J, Lahu S, Mayer K, Bernlochner I, Gewalt S, et al. Ticagrelor or prasugrel in patients with acute coronary syndrome in relation to estimated glomerular filtration rate. JACC Cardiovasc Interv. 2021;14:1857–66.
Hochholzer W, Wiviott SD, Antman EM, Contant CF, Guo J, Giugliano RP, et al. Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation. 2011;123:2681–9.
Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12:1360–420.
Costa F, van Klaveren D, James S, Heg D, Raber L, Feres F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet (London, England). 2017;389:1025–34.
Fujii T, Ikari Y. Additional effect of hemodialysis on mortality estimated from renal function in ischemic heart disease. Future Cardiol. 2022;18:857–65.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.
Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J. 2014;78:1684–92.
Acknowledgements
No acknowledgement.
Funding
No funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
No potential conflict of interest, including related consultancies, shareholdings, and funding grants.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Fujii, T., Amano, K., Kasai, S. et al. Impact of renal function on adverse bleeding events associated with dual antiplatelet therapy in patients with acute coronary syndrome. Cardiovasc Interv and Ther 39, 28–33 (2024). https://doi.org/10.1007/s12928-023-00963-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12928-023-00963-6